Deutsche Bank Ag\ Avita Medical, Inc. Transaction History

Deutsche Bank Ag\

$248 Billion
Q4 2024

A detailed history of Deutsche Bank Ag\ transactions in Avita Medical, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 22,821 shares of RCEL stock, worth $195,347. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,821

Previous 12,758 78.88%

Holding current value

$195,347

Previous $136,000 114.71%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$9.89 - $13.7 $99,523 - $137,863	10,063 Added 78.88%	22,821 $292,000
Q3 2024 Nov 13, 2024	BUY	$7.72 - $10.87 $995 - $1,402	129 Added 1.02%	12,758 $136,000
Q2 2024 Aug 14, 2024	SELL	$7.92 - $15.55 $20,797 - $40,834	-2,626 Reduced 17.21%	12,629 $100,000
Q1 2024 May 15, 2024	SELL	$12.56 - $18.31 $10,324 - $15,050	-822 Reduced 5.11%	15,255 $244,000
Q4 2023 Feb 14, 2024	BUY	$9.29 - $14.57 $149,355 - $234,241	16,077 New	16,077 $220,000
Q3 2023 Nov 09, 2023	BUY	$13.84 - $20.79 $57,519 - $86,403	4,156 Added 36.62%	15,505 $226,000
Q2 2023 Aug 14, 2023	BUY	$10.7 - $17.48 $121,434 - $198,380	11,349 New	11,349 $193,000
Q2 2022 Aug 11, 2022	SELL	$4.6 - $8.82 $65,002 - $124,635	-14,131 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$6.96 - $12.15 $10,843 - $18,929	-1,558 Reduced 9.93%	14,131 $120,000
Q4 2021 Feb 11, 2022	BUY	$11.72 - $19.66 $9,047 - $15,177	772 Added 5.18%	15,689 $188,000
Q3 2021 Nov 04, 2021	SELL	$16.73 - $20.9 $3,362 - $4,200	-201 Reduced 1.33%	14,917 $265,000
Q2 2021 Aug 11, 2021	BUY	$17.23 - $22.02 $260,483 - $332,898	15,118 New	15,118 $310,000

Others Institutions Holding RCEL

# of Institutions

Shares Held

6.31M

Call Options Held

28.8K

Put Options Held

17.2K

View Full List

About AVITA Medical, Inc.

Ticker RCEL
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 25,030,900
Market Cap $214M
Description
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and prop...

More about RCEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account